scholarly journals Recent advances in the management of non-small cell lung cancer

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 2110 ◽  
Author(s):  
Samira Shojaee ◽  
Patrick Nana-Sinkam
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Surgical Approaches ◽  
Small Cell Lung ◽  
Cancer Management ◽  
Recent Advances ◽  
Improved Outcomes ◽  
Significant Step

Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.

scholarly journals Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

2016 ◽  
Vol 11 (4) ◽  
pp. 453-474 ◽  
Author(s):  
Paul A. Bunn ◽  
John D. Minna ◽  
Alexander Augustyn ◽  
Adi F. Gazdar ◽  
Youcef Ouadah ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Biology ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Recent Advances ◽  
Improved Outcomes

scholarly journals P01.09 Improved Outcomes With Ramucirumab & Docetaxel in Metastatic Non-Small Cell Lung Cancer After Failure of Immunotherapy

2021 ◽  
Vol 16 (3) ◽  
pp. S239-S240
Author(s):  
R. Dawar ◽  
K. Gawri ◽  
E. Rodriguez ◽  
V. Thammineni ◽  
E. Saul ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Improved Outcomes

scholarly journals Paradigm shift in the management of metastatic Non-small Cell Lung Cancer

2021 ◽  
Author(s):  
Ruby Gupta ◽  
Melanie Smalley ◽  
Nwabundo Anusim ◽  
Vishal Jindal ◽  
Mandeep Singh Rahi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Paradigm Shift ◽  
Survival Rates ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Cancer Management ◽  
Chemotherapeutic Approach

Background: Lung cancer is one of the leading causes of cancer mortality in the US. The use of precision medicine in the past 10 years has significantly changed the therapeutic landscape of lung cancer. Management of advanced non-small cell lung cancer (NSCLC) has transitioned from a chemotherapeutic approach to targeted treatments and immunotherapeutic agents. Several tyrosine kinase inhibitors (TKIs) have been approved for patients with targeted mutations while patients who do not have driver mutations; immunotherapy has been recently approved as frontline therapy, which has resulted in marked improvement in overall survival and added a new tool in our armamentarium. Aims: The purpose of this review is to highlight recent advancements in diagnostic approach and management strategies in patients with metastatic NSCLC. Materials and methods: Published studies included in Medline (via PubMed) and National Comprehensive Cancer Network Guidelines were reviewed for data gathering. Conclusion: The use of next generation sequencing has significantly changed our understanding of molecular oncogenic mechanisms of lung cancer. These advancements have created a paradigm shift in the treatment strategies of metastatic lung cancer from primarily chemotherapeutic approach to increasing use of targeted therapies and immune check point inhibitors (ICI) leading to better survival rates and lesser toxicity.

Management of Pneumonitis and Neuropathy in Patients Receiving PD-1–Based Therapy for Non–Small-Cell Lung Cancer

2020 ◽  
Vol 16 (2_suppl) ◽  
pp. 4s-9s ◽  
Author(s):  
Marianne J. Davies ◽  
Anne C. Chiang
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Advanced Lung Cancer ◽  
Small Cell Lung ◽  
Case Examples ◽  
Improved Outcomes ◽  
Programmed Death

Immunotherapy with programmed cell death-1 (PD-1) receptor and programmed death ligand 1 (PD-L1) inhibitors has improved outcomes for certain patients with advanced lung cancer. As use of these therapies has expanded in first-line settings, in patients with different histologies, and in combinations with chemotherapeutic and targeted agents, more patients with lung cancer may benefit from these therapies. However, with expanded use comes greater potential exposure to the immune-related adverse events (irAEs) associated with these immune checkpoint inhibitors (ICIs). This article uses two case examples to illustrate the presentation, evaluation, and management of pulmonary and neurologic symptoms in two patients receiving PD-1–based therapy for non–small-cell lung cancer. These cases illustrate the challenges associated with recognizing pneumonitis and neuropathy in patients receiving ICIs for lung cancer. Although pneumonitis and neuropathy are relatively rare irAEs, they can have devastating or even fatal outcomes if not promptly recognized and managed appropriately. Specific use of guideline-based, multidisciplinary management is emphasized, as illustrated in the Immuno-Oncology Essentials Care Step Pathways.

scholarly journals Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer

2019 ◽  
Vol 30 (1) ◽  
pp. 105-109 ◽  
Author(s):  
Hideyasu Yamada ◽  
Norihito Hida ◽  
Hiroaki Satoh ◽  
Tetsuya Yamagishi ◽  
Yoshinori Hiroshima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Double Cancer ◽  
Small Cell Lung ◽  
Improved Outcomes
Sign in / Sign up

Export Citation Format

Share Document